IL137146A0 - Hydroxamic and carboxylic acid derivatives - Google Patents
Hydroxamic and carboxylic acid derivativesInfo
- Publication number
- IL137146A0 IL137146A0 IL13714699A IL13714699A IL137146A0 IL 137146 A0 IL137146 A0 IL 137146A0 IL 13714699 A IL13714699 A IL 13714699A IL 13714699 A IL13714699 A IL 13714699A IL 137146 A0 IL137146 A0 IL 137146A0
- Authority
- IL
- Israel
- Prior art keywords
- hydroxamic
- carboxylic acid
- acid derivatives
- receptors
- tnf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9802073.8A GB9802073D0 (en) | 1998-01-30 | 1998-01-30 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
GBGB9819574.6A GB9819574D0 (en) | 1998-09-08 | 1998-09-08 | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
PCT/GB1999/000313 WO1999038843A1 (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
US09/239,603 US6100266A (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
IL137146A0 true IL137146A0 (en) | 2001-07-24 |
Family
ID=27269200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13714699A IL137146A0 (en) | 1998-01-30 | 1999-01-29 | Hydroxamic and carboxylic acid derivatives |
Country Status (18)
Country | Link |
---|---|
US (1) | US6100266A (zh) |
EP (1) | EP1051395B1 (zh) |
JP (1) | JP2002501943A (zh) |
CN (1) | CN100402496C (zh) |
AT (1) | ATE346041T1 (zh) |
AU (1) | AU735929B2 (zh) |
BR (1) | BR9908215A (zh) |
CA (1) | CA2317455C (zh) |
CY (1) | CY1106338T1 (zh) |
DE (1) | DE69934094T2 (zh) |
DK (1) | DK1051395T3 (zh) |
ES (1) | ES2277424T3 (zh) |
HK (1) | HK1029330A1 (zh) |
HU (1) | HUP0100597A3 (zh) |
IL (1) | IL137146A0 (zh) |
NO (1) | NO326266B1 (zh) |
PL (1) | PL200418B1 (zh) |
WO (1) | WO1999038843A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
ES2281346T3 (es) * | 1999-06-04 | 2007-10-01 | Astrazeneca Ab | Inhibidores de metaloproteinasas. |
US20030199571A1 (en) * | 1999-12-24 | 2003-10-23 | Gordon Bruton | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
WO2001062750A1 (en) * | 2000-02-21 | 2001-08-30 | Astrazeneca Ab | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
IL150806A0 (en) * | 2000-02-21 | 2003-02-12 | Astrazeneca Ab | Piperidine-and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
IL152990A0 (en) * | 2000-05-25 | 2003-06-24 | Smithkline Beecham Plc | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides |
FR2827859B1 (fr) * | 2001-07-30 | 2005-09-23 | Lipha | Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete |
GB0119473D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca | Compounds |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0119472D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
US7511144B2 (en) | 2001-09-07 | 2009-03-31 | Kaken Pharmaceutical Co., Ltd. | Reverse hydroxamic acid derivatives |
GB0128378D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel Compounds |
GB0128376D0 (en) * | 2001-11-27 | 2002-01-16 | Smithkline Beecham Plc | Novel compounds |
SE0301922D0 (sv) * | 2003-06-27 | 2003-06-27 | Astrazeneca Ab | Novel compounds |
AU2006316552B2 (en) * | 2005-11-24 | 2012-06-07 | Merck Serono Sa | N-hydroxyamide derivatives and use thereof |
WO2007141029A1 (en) * | 2006-06-08 | 2007-12-13 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Specific protease inhibitors and their use in cancer therapy |
SG186795A1 (en) | 2010-07-08 | 2013-02-28 | Kaken Pharma Co Ltd | N-hydroxyformamide derivative and medicament containing same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4267293A (en) * | 1992-05-01 | 1993-11-29 | British Biotech Pharmaceuticals Limited | Use of MMP inhibitors |
JPH11504646A (ja) * | 1995-05-10 | 1999-04-27 | カイロサイエンス・リミテッド | 金属プロテアーゼとtnfの放出を抑制するペプチド化合物およびその治療的使用 |
KR20000022532A (ko) * | 1996-06-27 | 2000-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | 아릴(설파이드, 설폭시드 및 설폰)유도체 및 이를 활성 성분으로 함유하는 약물 |
KR20000048639A (ko) * | 1996-09-27 | 2000-07-25 | 로렌스 티. 마이젠헬더 | 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산 |
US5962481A (en) * | 1996-10-16 | 1999-10-05 | American Cyanamid Company | Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
WO1998039316A1 (en) * | 1997-03-04 | 1998-09-11 | Monsanto Company | N-hydroxy 4-sulfonyl butanamide compounds |
US5985900A (en) * | 1997-04-01 | 1999-11-16 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
TR199903287T2 (xx) * | 1997-07-31 | 2000-09-21 | Abbott Laboratories | Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri. |
-
1999
- 1999-01-29 BR BR9908215-2A patent/BR9908215A/pt not_active Application Discontinuation
- 1999-01-29 AT AT99902703T patent/ATE346041T1/de active
- 1999-01-29 ES ES99902703T patent/ES2277424T3/es not_active Expired - Lifetime
- 1999-01-29 EP EP99902703A patent/EP1051395B1/en not_active Expired - Lifetime
- 1999-01-29 JP JP2000530080A patent/JP2002501943A/ja active Pending
- 1999-01-29 IL IL13714699A patent/IL137146A0/xx active IP Right Grant
- 1999-01-29 CN CNB998024937A patent/CN100402496C/zh not_active Expired - Fee Related
- 1999-01-29 WO PCT/GB1999/000313 patent/WO1999038843A1/en active IP Right Grant
- 1999-01-29 DK DK99902703T patent/DK1051395T3/da active
- 1999-01-29 DE DE69934094T patent/DE69934094T2/de not_active Expired - Lifetime
- 1999-01-29 CA CA2317455A patent/CA2317455C/en not_active Expired - Fee Related
- 1999-01-29 HU HU0100597A patent/HUP0100597A3/hu unknown
- 1999-01-29 US US09/239,603 patent/US6100266A/en not_active Expired - Fee Related
- 1999-01-29 AU AU22914/99A patent/AU735929B2/en not_active Ceased
- 1999-01-29 PL PL342184A patent/PL200418B1/pl not_active IP Right Cessation
-
2000
- 2000-07-28 NO NO20003868A patent/NO326266B1/no not_active IP Right Cessation
- 2000-12-14 HK HK00108043A patent/HK1029330A1/xx not_active IP Right Cessation
-
2007
- 2007-02-22 CY CY20071100255T patent/CY1106338T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2277424T3 (es) | 2007-07-01 |
ATE346041T1 (de) | 2006-12-15 |
CN1289322A (zh) | 2001-03-28 |
HUP0100597A2 (hu) | 2001-08-28 |
DE69934094D1 (de) | 2007-01-04 |
CA2317455A1 (en) | 1999-08-05 |
WO1999038843A1 (en) | 1999-08-05 |
CN100402496C (zh) | 2008-07-16 |
PL342184A1 (en) | 2001-05-21 |
NO326266B1 (no) | 2008-10-27 |
DE69934094T2 (de) | 2007-06-06 |
PL200418B1 (pl) | 2009-01-30 |
BR9908215A (pt) | 2000-11-28 |
NO20003868L (no) | 2000-07-28 |
AU735929B2 (en) | 2001-07-19 |
HUP0100597A3 (en) | 2001-12-28 |
DK1051395T3 (da) | 2007-04-02 |
EP1051395A1 (en) | 2000-11-15 |
CY1106338T1 (el) | 2011-10-12 |
EP1051395B1 (en) | 2006-11-22 |
US6100266A (en) | 2000-08-08 |
JP2002501943A (ja) | 2002-01-22 |
AU2291499A (en) | 1999-08-16 |
CA2317455C (en) | 2011-01-25 |
HK1029330A1 (en) | 2001-03-30 |
NO20003868D0 (no) | 2000-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL137146A0 (en) | Hydroxamic and carboxylic acid derivatives | |
EP1119362A4 (en) | METHOD OF USING TETRACYCLINE COMPOUNDS TO INCREASE INTERLEUKIN-10 PRODUCTION | |
PL314300A1 (en) | Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases | |
FI971412A (fi) | Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä | |
YU6602A (sh) | Pirimidin-2,4,6-trion metaloproteinazni inhibitori | |
CY1109328T1 (el) | Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου | |
EP0863757A4 (zh) | ||
MX9602874A (es) | Guanilhidrazonas para el tratamiento de condiciones inflamatorias. | |
NO20002440D0 (no) | Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet | |
MY133125A (en) | Novel dihydroxyhexanoic acid derivatives | |
GB0003025D0 (en) | Novel compounds | |
ATE247650T1 (de) | Hydroxamsäure- und carbonsäurederivative | |
ATE394117T1 (de) | Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen | |
IT1294932B1 (it) | Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie | |
RU99111991A (ru) | Способ повышения солестойкости риса | |
MX9704740A (es) | Monomeros de 3,3-(disustituido)ciclohexan-1-ol y compuestos relacionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed |